title: Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.
authors.affiliation: Department of Pharmacology, AP-HP, Saint-Louis Hospital, Inserm, U976 Université Paris Diderot, Sorbonne Paris Cité, UMR-S-976, Paris lauriane.goldwirt@aphp.fr.
authors.forename: L
authors.initials: L
authors.lastname: Goldwirt
authors.affiliation: Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris.
authors.forename: I
authors.initials: I
authors.lastname: Chami
authors.affiliation: INSERM, IAME, UMR 1137, Université Paris Diderot, Paris.
authors.forename: J-P
authors.initials: JP
authors.lastname: Feugeas
authors.affiliation: Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Pages
authors.affiliation: Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris.
authors.forename: F
authors.initials: F
authors.lastname: Brunet-Possenti
authors.affiliation: Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Allayous
authors.affiliation: Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris.
authors.forename: B
authors.initials: B
authors.lastname: Baroudjian
authors.affiliation: Deparment of Pharmacy, AP-HP, Saint-Louis Hospital, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Madelaine
authors.affiliation: Department of Pharmacology, AP-HP, Saint-Louis Hospital, Inserm, U976 Université Paris Diderot, Sorbonne Paris Cité, UMR-S-976, Paris.
authors.forename: H
authors.initials: H
authors.lastname: Sauvageon
authors.affiliation: Department of Pharmacology, AP-HP, Saint-Louis Hospital, Inserm, U976 Université Paris Diderot, Sorbonne Paris Cité, UMR-S-976, Paris.
authors.forename: S
authors.initials: S
authors.lastname: Mourah
authors.affiliation: Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris Inserm, U 976, Paris Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Lebbé
mesh_terms: D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000188:drug therapy*; D009154:Mutation / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012878:Skin Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000097:blood*
chemical_list: D007211:Indoles; D013449:Sulfonamides; D048493:Proto-Oncogene Proteins B-raf